Hypertension Rx Labels Should Include Product-Specific CV Data – Cmte.
Executive Summary
Data on antihypertensives that have shown cardiovascular endpoint benefits in well-controlled trials should be included in labeling, FDA and the Cardiovascular & Renal Drugs Advisory Committee agreed at a June 15 meeting
You may also be interested in...
Hypertension Labeling Should Say Classes Are All Effective, But Unequally So
Antihypertensive drug class labeling for cardiovascular outcomes should specify that some classes of agents are more effective at reducing such events than others, members of FDA's Cardiovascular & Renal Drugs Advisory Committee said
Hypertension Labeling Should Say Classes Are All Effective, But Unequally So
Antihypertensive drug class labeling for cardiovascular outcomes should specify that some classes of agents are more effective at reducing such events than others, members of FDA's Cardiovascular & Renal Drugs Advisory Committee said
Drug Safety Stays At Top Of FDA’s Agenda With New Guidances In The Works
Drug safety will remain a primary focus of FDA's guidance development efforts, according to the Center for Drug Evaluation & Research's 2006 guidance agenda